Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global bursitis treatment market was valued at USD 687.4 million in 2024. The market is projected to grow from USD 739.2 million in 2025 to USD 1.12 billion by 2032, exhibiting a CAGR of 7.1% during the forecast period.
Bursitis treatments encompass therapeutic interventions targeting inflammation of the bursae - small fluid-filled sacs that cushion bones, tendons and muscles near joints. The condition primarily affects high-mobility areas including shoulders, elbows, hips and knees, causing localized pain, swelling and restricted movement. Standard treatment modalities include analgesics for pain management, anti-inflammatory drugs like NSAIDs, corticosteroid injections for severe inflammation, and antibiotics for infectious bursitis cases. In refractory cases, surgical bursectomy may be indicated, though this represents less than 5% of treatment interventions.
Market expansion is being primarily driven by the rising geriatric population susceptible to musculoskeletal disorders, with individuals over 40 accounting for 71% of diagnoses. The increasing prevalence of sports-related injuries among young adults (growing at 4.8% annually) further propels demand. Recent innovations in ultrasound-guided injections and the development of longer-acting corticosteroid formulations (lasting 3-4 months versus traditional 4-6 weeks) are enhancing treatment efficacy. However, market growth faces constraints including side effects associated with prolonged corticosteroid use and reimbursement challenges for advanced biologics - penetration of which remains below 15% in most markets.
Increasing Prevalence of Musculoskeletal Disorders
The global bursitis treatment market is driven by the rising incidence of musculoskeletal conditions, particularly among aging populations. Approximately 15% of adults over 65 experience bursitis annually, creating sustained demand for treatment solutions.
Technological Advancements in Treatment Options
Innovative therapies such as ultrasound-guided injections and regenerative medicine approaches are gaining traction. The development of longer-acting corticosteroid formulations has improved treatment outcomes by 20-25% compared to traditional options.
Sports medicine specialists increasingly prefer minimally invasive approaches, with arthroscopic bursectomy procedures growing at 8.7% annually.
Expanding healthcare infrastructure in emerging markets is facilitating better access to specialized treatments, particularly in urban centers.
MARKET CHALLENGES
Diagnostic Difficulties
Bursitis symptoms frequently mimic other joint conditions, leading to an estimated 30% misdiagnosis rate in primary care settings. This creates challenges for appropriate treatment selection and market sizing accuracy.
Other Challenges
Reimbursement Limitations
Many advanced bursitis treatments face insurance coverage restrictions, particularly for repeat procedures, creating financial barriers for patients.
Treatment Resistance
Approximately 15-20% of chronic bursitis cases show poor response to first-line therapies, requiring more costly interventions.
Growing Preference for Conservative Management
Many healthcare providers now advocate initial non-invasive approaches for bursitis, delaying procedural interventions. Physical therapy referrals for bursitis have increased by 12% in the past five years, impacting pharmaceutical and procedural treatment volumes.
Expansion of Biologic Treatments
Platelet-rich plasma (PRP) and stem cell therapies for refractory bursitis cases represent a $350 million annual growth opportunity, with adoption rates increasing by 18% year-over-year in specialty clinics.
Home Treatment Solutions
The pandemic accelerated demand for at-care treatments, with the telehealth segment for musculoskeletal consultations growing 140% since 2020. This creates opportunities for digital therapeutic solutions and home rehabilitation products.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Corticosteroids dominate treatment protocols due to their potent anti-inflammatory properties in reducing bursa swelling. Antibiotics show growing importance for infectious bursitis cases while analgesics remain critical for pain management. The others category includes emerging biologic treatments showing promise for chronic cases. |
| By Application |
|
Hospital Pharmacies maintain strong distribution due to requirements for specialized injectable treatments and post-surgical care. Retail pharmacies lead in over-the-counter analgesic distribution while online pharmacies show fastest growth as consumers increasingly purchase self-care products digitally. |
| By End User |
|
Hospitals remain the primary treatment centers for severe bursitis cases requiring invasive procedures. Clinics see high volumes of initial diagnoses and mild cases, while sports medicine centers specialize in athletic injury management. Home care grows as patients manage chronic bursitis with prescribed therapies. |
| By Treatment Approach |
|
Medication approach remains most prevalent with pharmaceuticals forming the first-line defense against inflammation and pain. Physical therapy gains traction for rehabilitation while surgical approaches are limited to recalcitrant cases. Alternative therapies including acupuncture see growing adoption among chronic pain patients. |
| By Affected Area |
|
Shoulder bursitis represents the most clinically significant segment due to its impact on mobility and high prevalence among aging populations. Knee bursitis follows closely with notable incidence among athletes, while hip bursitis presents challenges in diagnosis and management due to complex anatomy. |
Bursitis Treatment Market Dominated by Pharmaceutical Giants and Specialty Manufacturers
The global bursitis treatment market is highly competitive with established pharmaceutical companies holding significant market share. Teva Pharmaceutical leads the segment with its comprehensive portfolio of anti-inflammatory drugs and corticosteroid treatments. Other major players like Sun Pharmaceutical Industries and Perrigo Company have strengthened their position through strategic acquisitions and expanding their generic drug offerings. The market structure shows a mix of large multinational corporations and specialized manufacturers focusing on musculoskeletal treatments.
Niche players like Arbor Pharmaceuticals and Crecent Therapeutics are gaining traction through targeted therapies for chronic bursitis cases. Bioanalytical Systems occupies a unique position by providing specialized diagnostic solutions for inflammatory conditions. Emerging markets are seeing growth from regional manufacturers like Arinna Lifesciences Private, particularly in cost-sensitive treatment segments. Pipeline developments from these companies are expected to intensify competition in the coming years.
List of Key Bursitis Treatment Companies ProfiledSun Pharmaceutical Industries
Arbor Pharmaceuticals
Crecent Therapeutics
Arinna Lifesciences Private
Pfizer Inc.
Bayer AG
GlaxoSmithKline plc
Sanofi
Eli Lilly and Company
AbbVie Inc.
The global Bursitis Treatment market was valued at $X million in 2024 and is projected to reach $Y million by 2031, growing at a CAGR of Z% during the forecast period. Conservative treatments account for approximately 75% of market revenue, with corticosteroids, antibiotics, and analgesics being the primary drug classes. The market is shifting toward non-invasive solutions, driven by patient preference for reduced recovery times and lower medical costs.
Other TrendsIncreasing Prevalence in Aging Populations
With over 40% of bursitis cases occurring in adults aged 40+, the market is experiencing demographic-driven growth. Age-related joint degeneration and increased physical activity among elderly populations contribute to rising case numbers, particularly in developed regions with aging demographics.
Expansion of Distribution ChannelsRetail pharmacies currently dominate distribution channels with a 45% market share, but online pharmacies are projected to grow at 9% CAGR through 2031. This reflects broader pharmaceutical e-commerce trends and improved patient access to OTC treatments like analgesics and topical solutions.
Regional Market Variations
North America holds the largest market share (38%) due to high healthcare expenditure and diagnostic rates, while Asia-Pacific shows the fastest growth (7.2% CAGR) driven by improving healthcare infrastructure and rising awareness of musculoskeletal disorders.
Technological Advancements in Drug DeliveryInnovations in targeted drug delivery systems and longer-acting corticosteroid formulations are gaining traction. Major players like Teva Pharmaceutical and Sun Pharmaceutical are investing in R&D to develop more effective localized treatments with reduced systemic side effects.
Regional Analysis: Bursitis Treatment MarketEurope
Europe represents the second largest market for bursitis treatments, with Germany, France and UK leading adoption. The region shows preference for conservative therapies before invasive options. Strict regulations govern corticosteroid use, creating demand for safer alternatives. Growing sports medicine sector and government initiatives for musculoskeletal health are driving market growth. Eastern European countries are emerging as growth hotspots due to improving healthcare access and rising medical tourism for orthopedic treatments.
Asia-Pacific
Asia-Pacific is the fastest growing market fueled by increasing healthcare expenditure and rising disease awareness. Japan leads in advanced treatment adoption while China and India show explosive growth potential. Traditional medicine approaches coexist with modern treatments. Market challenges include price sensitivity and uneven treatment access between urban and rural areas. Multinational companies are establishing local manufacturing to capture this high-growth market.
South America
Brazil dominates the South American bursitis treatment market with improving healthcare infrastructure. Economic volatility affects treatment affordability but government healthcare programs help maintain access. Physical therapies are widely adopted due to cost-effectiveness. The region shows growing interest in biologic treatments but reimbursement challenges limit adoption. Local manufacturers are increasing production of generic NSAIDs and corticosteroids.
Middle East & Africa
The MEA market shows moderate growth with GCC countries driving demand through medical tourism and premium healthcare services. South Africa has the most developed treatment market on the continent. Limited local manufacturing results in dependence on imports. Traditional healing methods remain popular in rural areas. Market growth is constrained by low awareness in some regions and infrastructure limitations outside major cities.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global bursitis treatment market was valued at USD 687.4 million in 2024 and is projected to reach USD 1.12 billion by 2032, exhibiting a CAGR of 7.1% during the forecast period.
-> Key players include Teva Pharmaceutical, Sun Pharmaceutical Industries, Perrigo Company, and Arbor Pharmaceuticals, among others.
-> Key growth drivers include rising geriatric population, increasing sports-related injuries, and advancements in treatment modalities.
-> North America holds the largest market share, while Asia-Pacific is expected to show the highest growth rate.
-> Emerging trends include ultrasound-guided injections, longer-acting corticosteroid formulations, and development of advanced biologics.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates